AstraZeneca’s Forxiga approved in EU to treat symptomatic chronic heart failure
Forxiga is already approved in more than 100 countries worldwide, to treat patients with type-2 diabetes (T2D), HFrEF…
We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.
ContinueLearn More X
08 Feb 23
Forxiga is already approved in more than 100 countries worldwide, to treat patients with type-2 diabetes (T2D), HFrEF…
07 Feb 23
Genetika+ platform allows assessment of the functional effects of drugs directly on human neurons and comprises more than…
06 Feb 23
Trodelvy is a Trop-2 directed antibody-drug conjugate, indicated for previously treated patients with metastatic hormone receptor (HR)-positive, human…
03 Feb 23
Tezspire is a human monoclonal antibody that inhibits the action of TSLP, a key epithelial cytokine that plays…
02 Feb 23
The US FDA approval of Jesduvroq is based on results from the ASCEND-D trial, which evaluated the efficacy…
31 Jan 23
The collaboration aims to co-develop and co-commercialise Arcellx’s late-stage product candidate CART-ddBCMA, a T-cell therapy that uses Arcellx’s…
30 Jan 23
Jaypirca is the first BTK inhibitor specifically approved for patients with mantle cell lymphoma previously treated with a…
27 Jan 23
The EC approval is based on results from Phase 3 DESTINY-Breast04 clinical trial, in which Enhertu reduced the…
The US drugmaker intends to start initial production from the expanded Research Triangle Park this year, with full…
24 Jan 23
The licensing agreement for fruquintinib, which provides a potential new treatment option for patients with refractory metastatic colorectal…